Indication Finder

Indication Finder™:  A Repurposing Hunt

In keeping with our commitment to crowdsourcing and transparency, we invite you to participate in a unique exercise.  The U.S. National Center for Advancing Translational Sciences (NCATS), a division of NIH, has posted a list of 58 clinical stage compounds that were, until recently, being developed by pharmaceutical companies for various indications.  We expect that some of these compounds would be good candidates for Transparency Life Sciences’ approach to drug development.  We need your help in deciding which to pursue and the indications you think could be most promising.  Our Indication Finder™ (TLS-IF) has been developed to assist in this process.  Here's how it works:

  • NCATS has linked useful background information to the descriptions of all compounds. Once you have familiarized yourself with the compound and its background, the TLS-IF should take only 10-15 minutes to complete.  There is no limit to how many you can try. 
  • The compounds you help select using TLS-IF may become TLS development projects.  If so, they will be developed using Protocol Builder™, TLS’s proprietary crowdsourcing platform for designing better clinical trials.

To get started:
Please review the list and identify the compounds you believe have potential for further development.  Once you have reviewed enough information to assess the compound, complete an Indication Finder for each compound of interest, telling us how you think we should develop the compound along with the basis for your recommendations.  Feel free to provide your views on multiple compounds.  Happy hunting!

 

Compound Name Mechanism of Action Original Development Indication Administration (CNS Penetrant+)

AVE5530

canosimibe

Begin Indication Finder
Acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) inhibitor

Cholesterol absorption inhibitor
Hypercholesterolemia Oral

SSR149744C

celivarone

Begin Indication Finder
Anti-arrhythmic, Vaughan Williams Class I to IV Maintenance of sinus rhythm in atrial fibrillation patients

Prevention of shocks and major clinical outcomes in patients with implanted cardiac defibrillator
Oral

PF-05416266

senicapoc
(ICA-17043)

Begin Indication Finder
Calcium-activated potassium channel blocker (KCa3.1), intermediate-conductance Sickle cell disease

Asthma
Oral

ABT-639

Begin Indication Finder
Calcium channel, voltage-gated (Cav3.2, T-type) blocker Pain Oral
(Yes)

CP-945598

otenabant

Begin Indication Finder
Cannabinoid receptor 1 (CB1) antagonist Obesity Oral
(Yes)

LY2828360

Begin Indication Finder
Cannabinoid receptor 2 (CB2) agonist Osteoarthritis pain Oral
(Yes)

AZD1981

Begin Indication Finder
Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2)/prostaglandin D2 (DP2) receptor antagonist Asthma

Chronic obstructive pulmonary disease
Oral

SSR150106

Begin Indication Finder
Chemokine receptor antagonist (TNFα release) Rheumatoid arthritis pain Oral

AZD2423

Begin Indication Finder
Chemokine (C-C motif) receptor 2 (CCR2) antagonist Chronic obstructive pulmonary disease

Pain
Oral

PF-04136309

Begin Indication Finder
Chemokine (C-C motif) receptor 2 (CCR2) antagonist Chronic osteoarthritis pain Oral
(No)

CE-326597

Begin Indication Finder
Cholecystokinin 1 receptor (CCK-1R) (or CCKA receptor) agonist Obesity in type II diabetes Oral

BMS-562086

pexacerfont

Begin Indication Finder
Corticotropin-releasing factor 1 (CRF1) receptor antagonist Major depressive disorder

Generalized anxiety disorder

Irritable bowel syndrome
Oral
(Yes)

JNJ-39269646

Begin Indication Finder
Fast dissociating D2/D3/5-HT6 antagonist Schizophrenia Oral
(Yes)

ZD4054

zibotentan

Begin Indication Finder
Endothelin receptor A (ETA) antagonist Oncology

Pulmonary artery hypertension
Oral

PF-00913086

prinaberel
(ERB-041)

Begin Indication Finder
Estrogen receptor β (ERβ, ESR2) agonist/nuclear receptor 3A2 (NR3A2) agonist Endometriosis Oral

LY500307

Begin Indication Finder
Estrogen receptor β (ERβ, ESR2) agonist/nuclear receptor 3A2 (NR3A2) agonist Benign prostatic hyperplasia

Lower urinary tract symptoms
Oral

XRP0038

Riferminogene pecaplasmid, NV1FGF, temusi

Begin Indication Finder
Non-viral fibroblast growth factor 1 (NV1FGF) Critical limb ischemia Intramuscular
(No)

AZD7325

Begin Indication Finder
γ-Aminobutyric acid (GABA) A receptor, alpha 2 (GABAA α2) agonist Generalized anxiety disorder Oral
(Yes)

AZD3355

lesogaberan

Begin Indication Finder
γ-Aminobutyric acid (GABA) B receptor, 1 (GABAB1) agonist Gastroesophageal reflux disease Oral

PF-05190457

Begin Indication Finder
Ghrelin receptor (growth hormone secretagogue 1a receptor, GHS-1aR) inverse agonist, competitive antagonist Type II diabetes Oral
(Yes)

AZD1656

Begin Indication Finder
Glucokinase (GK) activator Diabetes Oral

BMS-820132

Begin Indication Finder
Glucokinase (GK) activator Type II diabetes Oral

PF-03463275

Begin Indication Finder
Glycine transporter 1 (GlyT1) inhibitor

Solute carrier family 6 (neurotransmitter transporter, glycine), member 9 (SLC6A9) inhibitor
Schizophrenia Oral
(Yes)

HMR1766

ataciguat

Begin Indication Finder
Soluble guanylate cyclase (sGC) activator Angina pectoris

Peripheral artery disease

Neuropathic pain
Oral

GSK1004723

Begin Indication Finder
Histamine H1/H3 receptor antagonist Allergic rhinitis Topical
(No)

GSK835726

Begin Indication Finder
Histamine H1/H3 receptor antagonist Allergic rhinitis Oral
(No)

ABT-288

Begin Indication Finder
Histamine H3 receptor antagonist Cognition
(cognitive deficits of schizophrenia)
Oral
(Yes)

PF-03654746

Begin Indication Finder
Histamine H3 receptor antagonist Narcolepsy

Cognition

Attention deficit hyperactivity disorder

Allergic rhinitis
Oral
(Yes)

CE-210666

Begin Indication Finder
5-Hydroxytryptamine 1B receptor (5-HT1B) antagonist Depression Oral
(Yes)

CP-448187

elzasonan

Begin Indication Finder
5-Hydroxytryptamine 1B receptor (5-HT1B) antagonist Depression Oral
(Yes)

PH-670187

dermaciclane, EGIS-3886

Begin Indication Finder
5-Hydroxytryptamine 2A/2C receptor (5-HT2A/2C) antagonist Generalized anxiety disorder Oral
(Yes)

PF-04995274

Begin Indication Finder
5-Hydroxytryptamine 4 receptor (5-HT4) partial agonist Gastroesophageal reflux disease

Alzheimer’s disease
Oral
(Yes)

JNJ-18038683

Begin Indication Finder
5-Hydroxytryptamine 7 receptor (5-HT7) antagonist Major depressive disorder Oral
(Yes)

LY2590443

Begin Indication Finder
5-Hydroxytryptamine 7A receptor (5-HT7A) antagonist Migraine Oral

MEDI2338

Begin Indication Finder
Interleukin-18 (IL-18) inhibitor Chronic obstructive pulmonary disease

Coronary heart disease
Intravenous, subcutaneous

PF-04191834

Begin Indication Finder
5-Lipoxygenase (5-LO) inhibitor Asthma

Chronic osteoarthritis pain
Oral
(Yes)

SD-7300

(SC-81490)

Begin Indication Finder
Matrix metalloproteinase 2, 9, and 13 (MMP-2, -9, -13) inhibitor Post-myocardial infarction cardiac remodeling

Disease-modifying osteoarthritis drug
Oral

AZD1236

Begin Indication Finder
Matrix metalloproteinase 9|12 (MMP9|MMP12) inhibitor Chronic obstructive pulmonary disease Oral

BMS-830216

Begin Indication Finder
Melanin-concentrating hormone 1 (MCH1) receptor antagonist Obesity Oral
(Yes)

AZD5904

Begin Indication Finder
Myeloperoxidase (MPO) inhibitor Chronic obstructive pulmonary disease

Multiple sclerosis
Oral

SAR103168

Begin Indication Finder
Multi-kinase inhibitor Liquid tumors (acute myeloid leukemia) Intravenous

ABT-089

Begin Indication Finder
Nicotinic acetylcholine receptor (nAChR) partial agonist (α4β2* subtypes) Alzheimer’s disease

Attention deficit hyperactivity disorder
Oral
(Yes)

CP-601927

Begin Indication Finder
Nicotinic acetylcholine receptor α4β2 (α4β2 nAChR) partial agonist Multiple CNS Oral
(Yes)

AZD0328

Begin Indication Finder
Nicotinic acetylcholine receptor alpha 7 (α7 nAChR) agonist Cognitive impairment Oral
(Yes)

JNJ-39393406

Begin Indication Finder
Nicotinic acetylcholine receptor, α7 (α7nAChR) positive allosteric modulator Cognitive impairment in schizophrenia Oral
(Yes)

GW274150

Begin Indication Finder
Inducible nitric oxide synthase (iNOS) inhibitor Migraine (acute and prophylaxis)

Asthma

Rheumatoid arthritis

Sepsis
Oral
(Poor)

SD-6010

(SC-84250)

Begin Indication Finder
Inducible nitric oxide synthase (iNOS) inhibitor Asthma

Osteoarthritis pain

Disease-modifying osteoarthritis drug
Oral

AZD7268

Begin Indication Finder
δ Opioid receptor agonist Anxiety

Depression
Oral
(Yes)

AVE8134

Begin Indication Finder
Peroxisome proliferator-activated receptor α (PPARα)/nuclear receptor 1C1 (NR1C1) agonist Type II diabetes Oral

AVE0847

Begin Indication Finder
Peroxisome proliferator-activated receptor α/γ (PPARα/γ)/nuclear receptor 1C1/1C3 (NR1C1/1C3) agonist Type II diabetes Oral

PF-05019702

(PRA-27)

Begin Indication Finder
Progesterone receptor (PR) antagonist/nuclear receptor 3C3C (NRC3C) antagonist Endometriosis Oral

AZD9056

Begin Indication Finder
Purinergic receptor 2X, ligand-gated ion channel, 7 (P2X7) antagonist Chronic obstructive pulmonary disease

Crohn’s disease

Osteoarthritis

Rheumatoid arthritis
Oral

LY2245461

Begin Indication Finder
Selective estrogen receptor modulator (SERM) Hot flashes in postmenopausal women Oral

AZD0530

saracatinib

Begin Indication Finder
Src tyrosine kinase inhibitor Oncology Oral

SB223412

talnetant

Begin Indication Finder
Tachykinin receptor/neurokinin 3 (NK3) receptor antagonist Cough

Chronic obstructive pulmonary disease

Schizophrenia

Irritable bowel syndrome

Overactive bladder
Oral
(Yes)

SAR115740

Begin Indication Finder
Transient receptor potential cation channel vanilloid 1 (TRPV1) antagonist Acute and chronic pain Oral

SSR97225

Begin Indication Finder
β-Tubulin-binding agent with dual mechanism Solid tumor Intravenous, injectable suspension

AZD2171

cediranib

Begin Indication Finder
Vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3 tyrosine kinase inhibitor Oncology Oral